| Characterisation and manipulation of docetaxel resistant prostate cancer cell lines AJ O'Neill, M Prencipe, C Dowling, Y Fan, L Mulrane, WM Gallagher, ... Molecular cancer 10, 1-13, 2011 | 222 | 2011 |
| The pharmacology of cancer resistance R O'CONNOR Anticancer research 27 (3A), 1267-1272, 2007 | 187 | 2007 |
| Induction of apoptosis in yeast and mammalian cells by exposure to 1, 10-phenanthroline metal complexes B Coyle, P Kinsella, M McCann, M Devereux, R O'Connor, M Clynes, ... Toxicology in Vitro 18 (1), 63-70, 2004 | 144 | 2004 |
| Synthesis and X-ray crystal structure of [Ag(phendio)2]ClO4 (phendio = 1,10-phenanthroline-5,6-dione) and its effects on fungal and mammalian cells M McCann, B Coyle, S McKay, P McCormack, K Kavanagh, M Devereux, ... Biometals 17, 635-645, 2004 | 120 | 2004 |
| MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma L O'driscoll, N Walsh, A Larkin, J Ballot, WS Ooi, G Gullo, R O'CONNOR, ... Anticancer research 27 (4B), 2115-2120, 2007 | 92 | 2007 |
| The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias R O’Connor, MG Ooi, J Meiller, J Jakubikova, S Klippel, J Delmore, ... Cancer chemotherapy and pharmacology 71, 1357-1368, 2013 | 90 | 2013 |
| Drug resistance in cancer–searching for mechanisms, markers and therapeutic agents R O'Connor, M Clynes, P Dowling, N O'Donovan, L O'Driscoll Expert opinion on drug metabolism & toxicology 3 (6), 805-817, 2007 | 82 | 2007 |
| CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance VG Martinez, R O'connor, Y Liang, M Clynes British journal of cancer 98 (3), 564-570, 2008 | 79 | 2008 |
| Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles V Lopes-Rodrigues, A Di Luca, J Mleczko, P Meleady, M Henry, M Pesic, ... Scientific reports 7 (1), 44541, 2017 | 76 | 2017 |
| A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer R O’Connor, M O’Leary, J Ballot, CD Collins, P Kinsella, DE Mager, ... Cancer chemotherapy and pharmacology 59, 79-87, 2007 | 70 | 2007 |
| A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin SA Glynn, P Gammell, M Heenan, R O'connor, Y Liang, J Keenan, ... British journal of cancer 91 (10), 1800-1807, 2004 | 69 | 2004 |
| Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts M Gottschalk, G Ivanova, DM Collins, A Eustace, R O'Connor, ... NMR in Biomedicine: An International Journal Devoted to the Development and …, 2008 | 65 | 2008 |
| Challenges of drug resistance in the management of pancreatic cancer R Sheikh, N Walsh, M Clynes, R O’Connor, R McDermott Expert review of anticancer therapy 10 (10), 1647-1661, 2010 | 64 | 2010 |
| Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells V Lopes-Rodrigues, A Di Luca, D Sousa, H Seca, P Meleady, M Henry, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1860 (3), 618-627, 2016 | 63 | 2016 |
| Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and … S Roche, G McMahon, M Clynes, R O’Connor Journal of Chromatography B 877 (31), 3982-3990, 2009 | 63 | 2009 |
| Enantioselective synthesis of sulindac AR Maguire, S Papot, A Ford, S Touhey, R O'Connor, M Clynes Synlett 2001 (01), 0041-0044, 2001 | 60 | 2001 |
| Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly (butylcyanoacrylate) nanoparticles M Simeonova, G Ivanova, V Enchev, N Markova, M Kamburov, C Petkov, ... Acta Biomaterialia 5 (6), 2109-2121, 2009 | 59 | 2009 |
| Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer … Y Liang, L O'Driscoll, S McDonnell, P Doolan, I Oglesby, K Duffy, ... International journal of cancer 111 (4), 484-493, 2004 | 59 | 2004 |
| A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance R O'Connor Current Cancer Drug Targets 9 (3), 273-280, 2009 | 57 | 2009 |
| Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients TJ Pugh, G Bebb, L Barclay, M Sutcliffe, J Fee, C Salski, R O'Connor, ... BMC cancer 7, 1-12, 2007 | 57 | 2007 |
